Literature DB >> 29777266

[No evidence for reduced late toxicity with dose reduction in the elective lymph node region in primary radiochemotherapy of head and neck tumors].

Mohammad Hreib1, Mechthild Krause2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29777266     DOI： 10.1007/s00066-018-1312-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  6 in total

1.  Non-inferiority trials are unethical because they disregard patients' interests.

Authors:  Silvio Garattini; Vittorio Bertele'
Journal:  Lancet       Date:  2007-10-23       Impact factor: 79.321

2.  Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity.

Authors:  Sandra Nuyts; Maarten Lambrecht; Fréderic Duprez; Jean-Francois Daisne; Dirk Van Gestel; Danielle Van den Weyngaert; Nele Platteaux; Yasmyne Geussens; Mia Voordeckers; Indira Madani; Wilfried De Neve
Journal:  Radiother Oncol       Date:  2013-08-13       Impact factor: 6.280

3.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

Authors:  K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

4.  Elective lymph node irradiation with intensity-modulated radiotherapy: is conventional dose fractionation necessary?

Authors:  Meena Bedi; Selim Firat; Vladimir A Semenenko; Christopher Schultz; Patrick Tripp; Roger Byhardt; Dian Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-01       Impact factor: 7.038

5.  Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

Authors:  J K Salama; K M Stenson; E O Kistner; B B Mittal; A Argiris; M E Witt; F Rosen; B E Brockstein; E E W Cohen; D J Haraf; E E Vokes
Journal:  Ann Oncol       Date:  2008-06-06       Impact factor: 32.976

6.  A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer.

Authors:  Johannes A Langendijk; Patricia Doornaert; Derek H F Rietveld; Irma M Verdonck-de Leeuw; C René Leemans; Ben J Slotman
Journal:  Radiother Oncol       Date:  2009-01-21       Impact factor: 6.280
  6 in total
  1 in total

Review 1.  Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.

Authors:  Jan Haussmann; Bálint Tamaskovics; Edwin Bölke; Freddy-Joel Djiepmo-Njanang; Kai Kammers; Stefanie Corradini; Matthias Hautmann; Pirus Ghadjar; Kitti Maas; Patrick J Schuler; Thomas K Hoffmann; Guido Lammering; Wilfried Budach; Christiane Matuschek
Journal:  Strahlenther Onkol       Date:  2019-10-04       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.